Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Public ClinicalTrials.gov record NCT04442269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis
Study identification
- NCT ID
- NCT04442269
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- dupilumab Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2020
- Primary completion
- Jul 26, 2023
- Completion
- Feb 8, 2024
- Last update posted
- Apr 3, 2025
2020 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Birmingham | Alabama | 35209 | — |
| Regeneron Study Site | Scottsdale | Arizona | 85251 | — |
| Regeneron Study Site | Bakersfield | California | 93301 | — |
| Regeneron Study Site | La Jolla | California | 92093 | — |
| Regeneron Study Site | Los Angeles | California | 90025 | — |
| Regeneron Study Site | Riverside | California | 92506 | — |
| Regeneron Study Site | Boise | Idaho | 83706 | — |
| Regeneron Study Site | Iowa City | Iowa | 52242 | — |
| Regeneron Study Site | New York | New York | 10032 | — |
| Regeneron Study Site | The Bronx | New York | 10461 | — |
| Regeneron Study Site | Columbus | Ohio | 43235 | — |
| Regeneron Study Site | DuBois | Pennsylvania | 15801 | — |
| Regeneron Study Site | Philadelphia | Pennsylvania | 19140 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04442269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04442269 live on ClinicalTrials.gov.